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Copyright © 2008 JCBN Summary Although patients with functional dyspepsia complain of epigastric symptoms, the
relation between these symptoms and gastric motility remains controversial. There are few
reports on the clinical course of functional dyspepsia, including changes in gastric motility,
observed over a considerably long period. We conducted a study to examine association
between changes in symptoms and changes in ultrasonographically evaluated gastric motility
over a long-term follow-up period in patients with functional dyspepsia. Forty patients (18
men, 22 women; mean age, 53.7 years) with functional dyspepsia were followed up by medical
interview, physical examination, endoscopy, and ultrasonography for gastric motility. Follow-
up ranged from 1.0 to 7.8 years (mean, 3.0 years). Ultrasonographic evaluation of gastric
motility included gastric emptying rate and antral contractions. During the follow-up period,
patients were treated with proton pump inhibitors, H2-blockers, or prokinetics. Symptoms
improved in 21 patients (group A), but symptoms persisted or worsened in 19 patients (group
B). There were no significant differences in clinical characteristics between the two groups.
Gastric motility improved in group A but not in group B. In conclusion, improved gastric
motility appears to correspond to and may explain improved symptoms in some patients with
functional dyspepsia.
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Introduction
Functional dyspepsia (FD) is a common condition often
encountered in clinical practice. Its pathophysiology has
been associated with many factors such as delayed gastric
emptying, impaired gastric accommodation, visceral hyper-
sensitivity,  Helicobacter pylori ( H. pylori) infection, and
psychological factors [1,  2]. However, the degree of
involvement of each factor is controversial. Whereas gastric
dysmotility has been reported in 30%–50% of FD patients
[2–4], placebo response has also been described in 50% of
FD patients, and studies suggesting that gastric dysmotility
plays only a small role in FD have also been reported [5].
Some reports describe improvement of FD symptoms in
patients with improved gastric motility [6], but the follow-
up periods in these studies were short. Reported long-term
follow-up studies are scarce.Ultrasonographic Study of Functional Dyspepsia
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Among the various methods for evaluating gastric motility,
abdominal ultrasonography (US) is simple, minimally
invasive, and provides real-time data [7, 8]. We conducted a
long-term follow-up study of patients with FD to examine
association between changes in symptoms and changes in
US-evaluated gastric motility.
Materials and Methods
Subjects
One hundred fourteen consecutive FD patients seeking
medical consultation at our hospital during the period 1994
through 2003 were recruited for this study. FD was
diagnosed on the basis of the American Gastroenterological
Association criteria for patients recruited from 1994 through
1999 and on the basis of the Rome II criteria for those
recruited beginning in 2000 [9,  10]. Peptic ulcer, reflux
esophagitis, and malignant neoplasm were ruled out by
upper gastrointestinal endoscopy in all patients. H. pylori
infection status was determined by endoscopic biopsy or
blood test for H. pylori antibodies. Patients with a history of
abdominal surgery, diabetes, or a neurologic disorder and
those taking drugs affecting gastrointestinal motility were
excluded from the study. During their initial medical
consultation, patients responded to a questionnaire evalu-
ating gastrointestinal symptoms and underwent abdominal
US evaluation of gastric motility.
Questionnaire
The questionnaire was filled out on the same day but prior
to US evaluation. Symptoms (i.e., upper abdominal pain,
bloating, nausea, early satiety, and heartburn) were scored
for severity as follows: 0, none; 1, mild; 2, moderate; and 3,
severe. Patients with heartburn were classified as having
gastro-esophageal reflux disease and were excluded. Scores
(excluding heartburn score) were added to yield a total
symptom score (minimum of 0 and maximum of 12). On the
basis of the predominant complaint, we divided patients into
three subgroups: those with a main symptom of pain as
having ulcer-like FD, those with bloating and early satiety as
having dysmotility-type FD, and those with another main
symptom as having non-specific FD. Smoking history and
medication types were also recorded.
Assessment of H. pylori infection
H. pylori infection status was determined by evaluating
Giemsa-stained biopsy specimens and serum IgG antibodies
against  H. pylori (E-plate, Eiken, Tokyo, Japan). Biopsy
specimens were taken from the antrum and corpus during
upper gastrointestinal endoscopy. Confirmation of the
presence of H. pylori by either of these examinations was
taken as positivity for H. pylori infection.
US assessment of gastric motility
We adopted the method of Fujimura and Kusunoki to as-
sess gastric motility ultrasonographically [11, 12]. In brief,
after an overnight fast, patients sat in a chair, leaned slightly
backwards, and drank 400 ml consommé soup (54.8 kJ,
0.38 g protein, 0.25 g fat, 2.3 g sugar per serving; Ajinomoto
Co, Tokyo, Japan). The cross-sectional area of the gastric
antrum was measured ultrasonographically. The frequency
of contractions of the antrum was also measured in real
time. An ultrasound probe was positioned vertically to
permit simultaneous visualization of the antrum, superior
mesenteric artery, and abdominal aorta.
We determined the following two variables: gastric
emptying rate (GER) and antral motility index (MI)
(Table 1). The GER was estimated by measuring the change
in the antral cross-sectional area between 1 min and 15 min
after ingestion of the consommé soup (Fig. 1A, B). The
MI was estimated by calculating the frequency of antral
contractions and changes in cross-sectional area over 3 min.
We defined baseline values as those obtained at the initial
consultation. The US examiner was unaware of the
responses to the questionnaire. The examinations were
conducted with an SSA-270A, 380A, or 390A (Toshiba,
Tokyo, Japan) ultrasound machine with a 3.5 MHz convex
probe. As previously reported, the normal range for GER is
45.4%–78.6% and that for MI is 6.49–9.57 [13].
Follow-up
All patients were followed up until December 2003. We
treated FD with drugs in the following order: prokinetics,
anti-ulcer drug, H. pylori eradication, and antidepressants
alone, and primarily used the most effective medicine.
Symptoms reported on the questionnaire were then analyzed
in relation to the US-based gastric motility findings obtained
during the initial consultation. Patients for whom follow-up
was less than 1 year were excluded from the analysis.
As a rule, gastric motility and abdominal symptoms
were evaluated annually or when symptoms changed. We
compared the baseline symptoms and baseline gastric
Table 1. US evaluation of gastric motility
US: ultrasonography
A1: antral cross-sectional relaxed area 1 min after ingestion
A15: antral cross-sectional relaxed area 15 min after ingestion
A (relaxed): antral cross-sectional relaxed area
A (contracted): antral cross-sectional contracted area
Gastric emptying rate (GER)
GER = (A1−A15) / A1 (%)
Antral contractions
Motility index (MI) = amplitude × frequency
amplitude: {A (relaxed) − A (contracted)} / A (relaxed) × 100
frequency: No. of antral contractions / 3 minD. Kamino et al.
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motility values with those at the final follow-up examina-
tion. We defined improvement of FD symptoms as improve-
ment by more than two points in the symptom score or a
symptom score of 0 at follow-up.
Statistical analysis
Values are shown as mean ± SD. The Mann-Whitney U test
was used to analyze differences in clinical characteristics
between groups of patients, and the Wilcoxon signed-rank
test was used to assess changes in gastric motility within
groups. A p value of less than 0.05 was considered statisti-
cally significant. This study was performed under approval
of the Ethics Committee of Hiroshima University.
Results
Patient characteristics
Of the original 114 FD patients, 74 were excluded because
of a short follow-up period (less than 1 year); thus, 40
patients (18 men, 22 women; mean age, 53.7 years; range,
16–82 years) completed the study. FD subtypes were as
follows: ulcer-like type, n = 2; dysmotility type, n = 15; and
non-specific type, n = 23. The mean follow-up period was
3.0 years (range, 1.0–7.8 years). Twelve patients were
treated with prokinetics, 20 with H2-blockers or proton
pump inhibitors, and 8 with other drugs. Twenty-nine
patients were examined for H. pylori infection, of which 14
were positive and 15 were negative. Eradication of H. pylori
was achieved in 4 of the 14 H. pylori-positive patients. No
organic disorder such as peptic ulcer or malignancy was
detected endoscopically during the follow-up period.
Change in symptoms
Symptoms of 21 of the 40 patients who were followed up
improved. These 21 patients were referred to as group A.
Sixteen patients had no change in symptoms, and symptoms
of 3 patients worsened. These 19 patients were referred to as
group B. Clinical characteristics are shown per group in
Table 2. There was no significant difference between the two
groups. During the initial medical consultation, the total
symptom score in group A was 4.89 ± 1.52; that in group B
was 4.47 ± 2.76. Follow-up scores were 1.95 ± 1.72 and
4.58 ± 2.69 for group A and group B, respectively. In group
A, the initial symptom score was significantly higher than
the follow-up score (p<0.01), but in group B there was no
significant difference between the initial symptom score and
the follow-up score.
Change in gastric motility
Gastric motility was assessed by US in all 40 patients.
Prevalence of abnormal GER at baseline was 50% (20/40)
and that of MI was 32.5% (13/40). No correlation between
gastric motility evaluated by US and symptom score of the
40 FD patients was noted (Fig. 2). In group A, however,
follow-up GER and MI values were significantly higher
than baseline values, whereas in group B, no significant
difference was observed between baseline and follow-up
values (Fig. 3).
Discussion
In this study, with a mean follow-up period of 3 years, we
observed significant improvement in US-evaluated gastric
motility that corresponded with improvement of symptoms
in patients with FD, indicating an association between
gastric motility and FD symptoms. In addition, no relation
was noted between the improvement in symptoms and age,
sex, smoking status, or H. pylori infection status.
These results suggest that gastric dysmotility plays an
important role in the pathophysiology of FD. Gastric
dysmotility in FD patients has been documented by many
previous studies [1–4, 14, 15], but in most of these studies,
results were based on one observation, and if subsequent
changes in gastric motility were reported, the follow-up
periods were short. In one study that evaluated FD patients
by means of gastric emptying scintigraphy, the authors
reported that subsequent re-evaluation 1 year after H. pylori
Fig. 1. Ultrasonographic assessment of gastric motility. Cross-
sectional view of the gastric antrum (arrows) at 1 min (A)
and 15 min (B) after ingestion of the consommé soup.Ultrasonographic Study of Functional Dyspepsia
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eradication therapy showed no change in the GER [16].
To the contrary, our long-term follow-up study showed
improvement in both symptoms and gastric motility. FD
symptoms usually persist. Thus, to understand the patho-
physiology of FD, it may be necessary to monitor patients
for a substantially long period.
In this study, we found no correlation between gastric
motility and symptom score, suggesting that symptom
severity may not relate directly to gastric dysmotility among
patients. Even though the gastric motility data may be the
same among patients, the sensation of symptoms experi-
enced by the patients may be different. In the same patient,
however, a change in gastric motility is associated with
change in symptom score. Thus gastric motility does appear
to affect symptom change in FD patients. Nevertheless, the
role of gastric dysmotility in the progression of FD may be
limited. Some of our group A patients showed no change in
gastric motility, and some of our group B patients showed
improved gastric motility. In addition, GER and MI rose in
some of our group A patients, but baseline GER and MI
Table 2. Clinical features of the two patient groups*
FD: functional dyspepsia, GER: gastric emptying rate, MI: motility index, US:
ultrasonography
*Differences were not significant
Group A (n = 21) Group B (n = 19)
Mean age upon recruitment (years) 50.5 ± 17.8 53.1 ± 16.9
Sex ratio (M/F) 8/13 10/9
Mean follow-up period (years) 3.09 ± 1.92 2.84 ± 1.60
FD subtype
ulcer-like type 1 1
dysmotility type 8 7
non-specific type 12 11
US findings (baseline)
GER 44.1 ± 20.2 50.9 ± 20.8
MI 7.29 ± 2.12 7.46 ± 2.59
Medications (n)
Prokinetic drugs 8 4
Anti-ulcer drugs 10 10
Helicobacter pylori infection (n)
positive 8 6
negative 8 7
Smoking status (n)
smoking 3 2
non-smoking 18 17
Fig. 2. Correlation between US-determined gastric motility and symptom score. No correlation was noted. US: ultrasonography, GER:
gastric emptying rate, MI: motility indexD. Kamino et al.
J. Clin. Biochem. Nutr.
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were already high in those patients. This finding suggests
that in the FD patients in whom there was no association
between symptoms and gastric dysmotility, other factors
could have been responsible for the pathogenesis of FD. We
did not evaluate adaptive relaxation of the proximal
stomach, which is the other motility factor associated with
FD. Association between FD and gastric dysmotility might
have increased if impaired gastric reservoir function had
been evaluated.
Prevalence of FD subtype in Japanese people is different
from that of Western people. Dysmotility-type dyspepsia is
the most common subtype in Japan [17]. In the present
study, non-specific-type dyspepsia was most frequent, and
prevalence of dysmotility-type was higher than that of
ulcer-like dyspepsia. Most of the non-specific type patients
in our study complained of either abdominal pain or
dysmotility symptoms such as early satiety or bloating, wuth
dysmotility being the most common symptom in this study.
Reports suggesting that FD subtypes have little association
with the pathophysiology and treatment of the disease are
numerous [1, 18, 19]. In the present study, there was no
significant difference in the distribution of the subtypes
between the two groups of patients. Moreover, there were
even some patients with ulcer-like FD in whom both
symptoms and gastric motility improved. These findings are
consistent with previously reported findings that prokinetics
improve not only abdominal fullness but also abdominal
pain of FD patients [20].
Many previous studies have shown a generally good
prognosis for FD, with improvement of symptoms in
approximately 50% of patients [18,  21–22]. This is
consistent with our results; however, it was difficult for us to
predict outcomes in patients on the basis of ultrasonographic
findings obtained during patients’ initial consultation
because there was no significant difference in baseline
gastric motility between the two groups. Moreover, because
patients were being treated with different medications, it
was impossible to say which drug contributed to improved
gastric motility. There is no consensus on the issue of which
drug is effective for FD [23–25]. Antidepressants and
placebo as well as acid inhibitors and promotility drugs are
reported to be effective, underscoring the notion that many
factors influence the pathophysiology of FD [5, 25, 26].
Our study group was small, and there is a need to
investigate the effects of various drugs on gastric motility in
patients with FD. Thus, further research into this common
disorder is warranted, and prospective randomized controlled
study is needed.
Although many methods exist for evaluation of gastric
motility, including evaluation of gastric accommodation
with a barostat or of gastric emptying by means of an isotope
or breath test, US offers a simple, less invasive, and real-
time approach [27]. US is a good method for repeat
evaluations. FD is characterized by delayed gastric emptying,
decreased antral contraction, and impaired reservoir
function of the proximal stomach [7,  8,  11,  12,  15]. We
evaluated gastric motility using a liquid meal that patients
did not usually take. However, delayed gastric emptying of
liquid is common in FD patients and is improved by
medication [4, 14]. The 54.8-kJ liquid meal we used in the
present study provided less energy content than a usual daily
meal. We have already shown that gastric emptying and MI
produced by this liquid meal are significantly lower in
patients with FD than in healthy subjects [12].
Overall, we conclude that improved gastric motility may
explain symptom improvement seen in some patients with
FD.
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